Polyiclc
Locally Advanced Gastric Adenocarcinoma
Mayo ClinicPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Locally Advanced Gastric Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUTICASONE Mayo Clinic | Phase 1/2 | B |
Sargramostim Mayo Clinic | Phase 1/2 | B |
FILGRASTIM Mayo Clinic | Phase 1/2 | B |
Sonidegib Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →